Retraction: Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NFκBp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats

Abstract

Full text

After this article [1] was published, concerns were raised about results presented in Figs 4–7. Specifically:

In response to queries about the experiments in Figs 6 and 7, the corresponding author stated that Fig 6J and 6P and Fig 7B, 7H, 7N and 7P are incorrect due to an error. They provided underlying images for all panels in Figs 4–8 and individual-level underlying data for the charts in Figs 2, 3 and 5–8, but the PLOS ONE Editors did not consider this to resolve concerns about the validity of the image data.

In light of the extent of the concerns listed above that question the reliability and validity of the reported results and conclusions, the PLOS ONE Editors retract this article.

SSAER and HMF agreed with the retraction and apologize for the issues with the published article.

Owing to the concerns about similarities with previously published content [2], published in 2021 by The Pharmaceutical Society of Japan [2], which is not offered under a CC BY license, Figs 4C, 5B–5D, 5G–5H, 6D and 6K–6L are excluded from this article’s [1] license. At the time of retraction, the article [1] was republished to note these exclusions in the legends of Figs 4–6 and the article’s copyright statement.